このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Viridian Therapeutics 将来の成長

Future 基準チェック /26

Viridian Therapeuticsは、48.3%と67.9%でそれぞれ年率48.3%で利益と収益が成長すると予測される一方、EPSはgrowで48.3%年率。

主要情報

48.3%

収益成長率

48.3%

EPS成長率

Biotechs 収益成長	28.1%
収益成長率	67.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	12 Jun 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

LSE:0K1R - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	115	-199	-236	-214	10
12/31/2025	0	-270	-212	-260	13
12/31/2024	0	-230	-178	-196	14
3/31/2024	0	-218	-168	-167	N/A
12/31/2023	0	-238	-185	-184	N/A
9/30/2023	0	-217	-181	-180	N/A
6/30/2023	1	-198	-163	-162	N/A
3/31/2023	2	-172	-136	-135	N/A
12/31/2022	2	-130	-95	-94	N/A
9/30/2022	2	-113	-77	-76	N/A
6/30/2022	1	-98	-68	-68	N/A
3/31/2022	2	-87	-65	-64	N/A
12/31/2021	3	-79	-55	-55	N/A
9/30/2021	3	-141	-48	-47	N/A
6/30/2021	3	-133	-41	-41	N/A
3/31/2021	2	-121	-33	-33	N/A
12/31/2020	1	-111	-30	-30	N/A
9/30/2020	2	-30	-28	-28	N/A
6/30/2020	3	-36	-32	-32	N/A
3/31/2020	5	-38	-33	-33	N/A
12/31/2019	4	-42	-36	-36	N/A
9/30/2019	4	-42	-37	-36	N/A
6/30/2019	4	-40	-34	-34	N/A
3/31/2019	4	-40	-32	-31	N/A
12/31/2018	8	-33	-27	-27	N/A
9/30/2018	9	-29	-26	-26	N/A
6/30/2018	10	-26	-25	-25	N/A
3/31/2018	8	-24	-28	-27	N/A
12/31/2017	4	-27	N/A	-28	N/A
9/30/2017	3	-26	N/A	-24	N/A
6/30/2017	3	-24	N/A	-21	N/A
3/31/2017	3	-21	N/A	-19	N/A
12/31/2016	3	-17	N/A	-15	N/A
9/30/2016	4	-17	N/A	-14	N/A
12/31/2015	5	-16	N/A	-13	N/A
12/31/2014	8	-6	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0K1R今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0K1R今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 0K1R今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0K1Rの収益 ( 67.9% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0K1Rの収益 ( 67.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0K1Rの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Viridian Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

First quarter 2024 earnings released: US$0.79 loss per share (vs US$1.61 loss in 1Q 2023)

Viridian Therapeutics, Inc., Annual General Meeting, Jun 17, 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: US$5.31 loss per share (vs US$4.05 loss in FY 2022)

Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer

Viridian Therapeutics, Inc. has filed a Follow-on Equity Offering.

Viridian Therapeutics, Inc. Announces Executive Changes

Third quarter 2023 earnings released: US$1.09 loss per share (vs US$0.86 loss in 3Q 2022)

Viridian Therapeutics, Inc. announced that it has received $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors

Viridian Therapeutics, Inc. announced that it expects to receive $185.000072 million in funding from a group of investors

Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors

Viridian Therapeutics, Inc. Announces Resignation of Kristian Humer as Chief Financial Officer

Viridian Therapeutics, Inc. Announces Executive Changes

Second quarter 2023 earnings released: US$1.27 loss per share (vs US$1.06 loss in 2Q 2022)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)

First quarter 2023 earnings released: US$1.61 loss per share (vs US$0.98 loss in 1Q 2022)

President recently bought US$101k worth of stock

President recently bought US$160k worth of stock

Full year 2022 earnings released: US$4.05 loss per share (vs US$6.66 loss in FY 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. Appoints Scott Myers as Chief Executive Officer

Viridian Therapeutics, Inc. Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (Ted)

High number of new and inexperienced directors

Viridian Therapeutics Announces First Patient Enrolled in the ‘Thrive’ Phase 3 Trial in Patients with Thyroid Eye Disease

Third quarter 2022 earnings released: US$0.86 loss per share (vs US$1.26 loss in 3Q 2021)

High number of new and inexperienced directors

Viridian Therapeutics, Inc Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

Viridian Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Viridian Therapeutics, Inc. Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting

High number of new and inexperienced directors

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$2.22 loss in 2Q 2021)

Viridian Therapeutics, Inc. Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

High number of new and inexperienced directors

Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

Viridian Therapeutics, Inc. to Report Q1, 2022 Results on May 12, 2022

High number of new and inexperienced directors

Viridian Therapeutics, Inc. announced that it expects to receive $75 million in funding from Hercules Capital, Inc.

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

High number of new and inexperienced directors

Viridian Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022

High number of new and inexperienced directors

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-002 to the U.S. Food and Drug Administration

Viridian Therapeutics Announces First Subject Dosed in Phase 1/2 Clinical Trial of VRDN-001 for Thyroid Eye Disease (TED)

High number of new and inexperienced directors

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘